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STRUCTURED ABSTRACT 
Objective: To evaluate cardiovascular (CV) outcomes in outpatients with 
coronary artery disease (CAD) living alone compared to those living with others. 
Methods: The prospeCtive observational LongitudinAl RegIstry oF patients with 
stable coronarY artery disease (CLARIFY) included outpatients with stable CAD. 
CLARIFY enrolled participants in 45 countries from November 2009 to July 2010, 
with 5 years of follow-up. Living arrangement was documented at baseline. The 
primary outcome was a composite of major adverse cardiovascular events 
(MACE) defined as CV death, myocardial infarction (MI), and stroke.  
Results: Among 32,367 patients, 3,648 patients were living alone (11.3%). After 
multivariate adjustment, there were no residual differences in MACE among 
patients living alone compared to those living with others (HR 1.04, 95% CI 0.92-
1.18, p=0.52), however there was significant heterogeneity in the exposure effect 
by sex (Pinteraction<0.01). Specifically, men living alone were at higher risk for 
MACE (HR 1.17, 95% CI 1.002-1.36, p=0.047) as opposed to women living alone 
(HR 0.82, 95% CI 0.65-1.04, p=0.1), predominantly driven by a heterogeneous 
effect by sex on MI (Pinteraction=0.006). There was no effect modification for MACE 
by age group (Pinteraction=0.3) although potential varying effects by age for MI 
(Pinteraction=0.046) and stroke (Pinteraction=0.05). 
Conclusions: Living alone was not associated with an independent increase in 
MACE, although significant sex-based differences were apparent. Men living 
alone may have a worse prognosis from CV disease than women, further 
analyses are needed to elucidate the mechanisms underlying this difference.   
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Trial registration: CLARIFY is registered in the ISRCTN registry of clinical trials 
(ISRCTN43070564). 
 
Keywords: social isolation, living alone, coronary artery disease, cardiovascular 
disease 
 
Abbreviations list: chronic obstructive pulmonary disease (COPD), congestive 
heart failure (CHF), coronary artery disease (CAD); coronary artery bypass graft 
(CABG), cardiovascular disease (CVD), electrocardiogram (ECG), major 
cardiovascular events (MACE), myocardial infarction (MI), percutaneous 
coronary intervention (PCI) 
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Key questions: 
What is already known about this subject? 
Patients living alone with coronary artery disease (CAD) may be at increased risk 
for cardiovascular (CV) events. As individuals with stable CAD live longer with 
advanced comorbidities, there is an important public health implication to 
determine if living status is independently associated with poor health outcomes.  
What does this study add? 
The CLARIFY registry included outpatients with CAD with 5 years of follow-up. 
Our study suggests that living alone in patients with stable CAD was not 
associated with an independent increase in major adverse cardiovascular events 
(MACE), although age and sex-based differences were apparent.  
How might this impact on clinical practice? 
Elderly patients and women living alone may have potentially lower CV risk, 
which warrants further confirmation.  
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Key Message: 
 The CLARIFY registry included outpatients with CAD with 5 years of follow-
up.  
 After multivariate adjustment, there were no differences in MACE among 
patients living alone compared to those living with others, however there was 
significant heterogeneity in the exposure effect by sex.  
 Men living alone were at higher risk for MACE as opposed to women living 
alone, driven by a heterogeneous effect by sex on MI (Pinteraction=0.006).  
 There was no effect modification for MACE by age group (Pinteraction=0.3) 
although potential varying effects by age for MI (Pinteraction=0.046) and stroke 
(Pinteraction=0.05).  
 Future large studies in patients with established CAD will evaluate patient 
social isolation using validated tools/scoring system, which will inform health 
care practitioners of patients with potential increased long-term CV risk, as 
well assist in forming beneficial psychosocial interventions.   
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INTRODUCTION 
Social isolation refers to the lack of contact an individual has with society, with 
living alone frequently used as a surrogate.(1) Living alone may lead to poor 
outcomes in patients with coronary artery disease (CAD) through a complex 
interaction between increased neurohormonal stress with accelerated 
atherosclerosis, less adherence to guideline recommended therapy and 
secondary prevention targets, increased anxiety and depression leading to more 
psychological distress, poor coping mechanisms/self-care, and less access to 
health care services.(2, 3) Previous analyses have sought to gain insight into the 
risk of living alone in patients with established cardiovascular disease (CVD). The 
effect of living alone has been variable due to the significant heterogeneity 
amongst the populations studied, with sub-group analysis showing potential 
effect modification by age and sex, and potential lower risk among women and 
elderly patients living alone.(4-7) 
 Patients with CAD are diverse with differences in ethnicity, socioeconomic 
status, location, and psychosocial factors which may play a role in the risk of 
recurrent CV events.(8) The prospeCtive observational LongitudinAl RegIstry oF 
patients with stable coronarY artery disease (CLARIFY) was initiated to improve 
knowledge about patients with stable CAD from a broad geographic 
perspective.(9)  As individuals with stable CAD live longer with advanced 
comorbidities, there is an important public health implication to determine if living 
status is independently associated with poor health outcomes. The objective of 
this analysis was to determine, in a stable CAD population, if living alone is 
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associated with increased CV risk. Given previous research, effect modification 
by sex and age group were further explored in this post-hoc analysis.   
 
METHODS 
STUDY DESIGN AND PATIENT SELECTION 
The CLARIFY study cohort included outpatients with stable CAD with 5 years of 
follow-up, the study methods and design were previously published.(9-12) 
Patients eligible for enrolment were those with stable CAD diagnosed by at least 
one of the following: 1) documented myocardial infarction (MI) (>3 months ago); 
2) coronary stenosis >50% on coronary angiography; 3) chest pain with 
myocardial ischemia determined by stress electrocardiogram (ECG), stress 
echocardiography, or myocardial imaging; or 4) history of revascularization by 
coronary artery bypass graft (CABG) surgery or percutaneous coronary 
intervention (PCI) (performed >3 months ago). Patients hospitalized for CVD 
within the previous 3 months (including for revascularization), patients for whom 
revascularization was planned, and patients with conditions expected to hamper 
participation of 5-year follow-up were excluded from participating in the study. A 
total of 32,703 subjects were enrolled in 45 countries, from November 2009 to 
July 2010 (Table S1). 
 
DATA COLLECTION 
The investigators completed standardised electronic case report forms at 
baseline and yearly at each visit for up to 5 years. Living arrangement status was 
 11 
documented as either “living alone” or “not living alone” at baseline. Further 
information collected at baseline included demographics; prior medical history 
and cardiovascular risk factors; current symptoms; physical examination; 
laboratory values (e.g., fasting blood glucose, hemoglobin A1c [HbA1c], 
cholesterol, triglycerides); and current chronic drugs regimen (i.e., those taken 
regularly by the patient for ≥7 days before entry in the registry). Data was 
recorded if an ECG was available for whether the patient was in sinus rhythm, 
atrial fibrillation/atrial flutter, paced rhythm, or left bundle branch block (LBBB). 
The remaining patients may not have had ECG data available or may be in 
another rhythm then above. Investigators reported number of vessels with 
disease and number of coronary territories with significant stenosis (>50%) 
independent of whether the patient had a recent angiogram (within 12 months). 
This data was investigator reported independent of the most recent available 
angiogram results and may not be mutually exclusive.  
For patients missing the yearly in-person visit, telephone contact with the 
patient, a designated relative or contact, or their physician was attempted. To 
ensure data quality, onsite-monitoring visits of 100% of the data in 5% of centres 
were selected at random, regular telephone contact with investigators to reduce 
missing data and loss to follow-up, and centralised verification of the electronic 
case report forms for completeness, consistency, and accuracy were undertaken.  
 
OUTCOMES 
At each annual follow-up visit, clinical outcomes occurring during the previous 12 
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months were recorded. The primary outcome of this analysis was major adverse 
cardiovascular events (MACE), which included CV death, nonfatal or fatal MI, 
and nonfatal or fatal stroke. Secondary outcomes were all-cause death, CV 
death, MI, stroke, unstable angina, and major bleeding (defined as leading to 
hospitalization or transfusion). CV death was defined as fatal MI or stroke, other 
CV death or death due to unknown cause; any MI or stroke followed by death in 
the subsequent 28 days was considered fatal. Events were accepted as reported 
by patients and physicians, without central adjudication, however all events were 
source verified during audits.  
The study was performed in accordance with the principles of the 
Declaration of Helsinki and was approved by the National Research Ethics 
Service, Isle of Wight, Portsmouth and Southeast Hampshire Research Ethics 
Committee, UK.  Approval was also obtained in all participating countries, in 
accordance with local regulations before recruitment of the first participant. All 
patients gave written informed consent to participate, in accordance with national 
and local guidelines. There was no patient/public involvement in this research 
study. CLARIFY is registered in the ISRCTN registry of clinical trials 
(ISRCTN43070564). 
 
STATISTICAL ANALYSIS  
All CLARIFY data were collected and analyzed at an independent academic 
statistics center at the Robertson Centre for Biostatistics, University of Glasgow, 
UK, which was responsible for managing the database, performing all analyses 
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and data storage. Baseline variables are summarized as means and standard 
deviations (SDs) or medians and interquartile ranges (IQRs) for continuous data, 
depending on the distribution of the data; and as counts and percentages for 
categorical data. In this post-hoc analysis, differences between patients living 
alone and those living with others were compared using Chi-squared tests or 
Fisher’s exact test for categorical variables as appropriate, and 2 sample t-tests 
or Wilcoxon Mann-Whitney tests for continuous variables, depending on the 
distribution of the data. A Cox proportional hazards model was used to assess 
the risk associated with living alone and time to first cardiovascular outcomes. 
Crude and multivariable adjusted hazards ratios (HRs) and corresponding 95% 
confidence intervals (CIs) were estimated after adjustment for age, sex, and 
geographic region; as well as baseline history of smoking, diabetes, peripheral 
arterial disease, MI, PCI, CABG, asthma/chronic obstructive pulmonary disease 
(COPD), and congestive heart failure (CHF). Additional clinical characteristics 
were also adjusted for, including baseline systolic blood pressure, diastolic blood 
pressure, left ventricular ejection fraction, and number of vessels with coronary 
artery stenoses. Heterogeneity was assessed with interaction testing between 
living status and sex, age group (<65 years, 65–74 years, ≥75 years), and history 
of prior MI at baseline for primary and secondary endpoints after multivariable 
adjustment. All p-values for the Cox proportional hazards models were obtained 
using the Wald test. 
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RESULTS 
A total of 32,367 patients were eligible for inclusion in the analysis with 3,648 
patients documented as living alone (11.3%) and 28,728 (88.8%) patients living 
with others. Table 1 and Table 2 includes baseline characteristics, study 
inclusion, previous medical history, CV risk factors, and symptom profile. The 
mean age for patients living alone was 67 (±10.66) years. Patients living alone 
were older, more likely to be female, predominantly white, less likely to be 
employed full time, and more likely to be retired than those living with others. 
More patients living alone were current smokers, had a history of atrial fibrillation, 
prior HF hospitalisation, history of peripheral arterial disease, and yet had less 
diabetes. Table 3 describes cardiovascular therapies. There was a high use of 
guideline recommended pharmacologic therapy in both groups, there was a 
lower number of patients living alone taking thienopyridines, beta-blockers, and 
statins.  
 
Table 1. Baseline Characteristics by Living Arrangement Status 
 Living alone (n=3648) Not living alone 
(n=28,728) 
p-value 
Age (years), mean (SD) 67.2 (10.7) 63.8 (10.4) <0.001 
Males (%) 2254 (61.8) 22857 (79.6) <0.001 
Body Mass Index (kg), 
median (25th, 75th 
quartiles),  
27 [25, 31] 27 [25, 30] 0.032 
Waist Circumference 
(cm), median (25th, 75th 
quartiles) 
96 [88, 105] 97 [89, 105] 0.01 
    
Ethnicity  (%)    
 White 2644 (72.5) 18304 (63.8) <0.001 
 South Asian  130 (3.6) 2285 (8.0)  
 Chinese  167 (4.6) 2573 (9.0)  
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 Japanese/Korean  142 (3.9) 893 (3.1)  
 Hispanic  110 (3.0) 1458 (5.1)  
 Black/African  44 (1.2) 294 (1.0)  
 Unknown  411 (11.3) 2921 (10.2)  
    
Employment status  
(%) 
   
 Employed full-time 605 (16.6) 7291 (25.4) <0.001 
 Employed part-time  227 (6.2) 2022 (7.0)  
 Unable to work  146 (4.0) 1119 (3.9)  
 Unemployed  143 (3.9) 1689 (5.9)  
 Retired  2415 (66.2) 15505 (54.0)  
 Other  112 (3.1) 1101 (3.8)  
    
Education level  (%)    
 Primary school (or 
less) 
1011 (27.7) 7561 (26.3) <0.001 
 Secondary school  1785 (49.0) 13251 (46.1)  
 College/University  852 (23.4) 7913 (27.6)  
    
Medical History  (%)    
Myocardial Infarction  2150 (59.0) 17251 (60.0) 0.20 
PCI  2051 (56.2) 16906 (58.9) 0.003 
CABG  907 (24.9) 6722 (23.4) 0.049 
Hospitalization for CHF  218 (6.0) 1294 (4.5) <0.001 
Internal Cardiac 
Defibrillator  
65 (1.8) 342 (1.2) 0.003 
Pacemaker  124 (3.4) 653 (2.3) <0.001 
Aortic abdominal 
aneurysm  
70 (1.9) 424 (1.5) 0.040 
Carotid Disease  350 (9.6) 2107 (7.3) <0.001 
Peripheral Arterial 
Disease  
425 (11.7) 2777 (9.7) <0.001 
Transient Ischemic 
Attack  
137 (3.8) 856 (3.0) 0.010 
Stroke  166 (4.6) 1135 (4.0) 0.082 
Atrial Fibrillation/Flutter  324 (8.9) 1960 (6.8) <0.001 
Family History of 
Premature CAD  
1120 (30.7) 8096 (28.2) 0.001 
Treated Hypertension  2638 (72.3) 20351 (70.9) 0.066 
Diabetes  977 (26.8) 8415 (29.3) 0.002 
Dyslipidemia  2773 (76.0) 21485 (74.8) 0.109 
Asthma/COPD  363 (10.0) 2031 (7.1) <0.001 
    
Smoking status   (%)    
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Current  536 (14.7) 3501 (12.2) <0.001 
Former  1505 (41.3) 13468 (46.9)  
Never 1607 (44.0) 11759 (40.9)  
    
Alcohol intake (number 
of drinks per week)  (%) 
   
0 1741 (47.7) 13684 (47.6) 0.032 
>0 and <20  1745 (47.8) 14025 (48.8)  
20-40  144 (4.0) 921 (3.2)  
>40  18 (0.5) 93 (0.3)  
    
Stimulant drinks 
consumed  (%) 
   
Coffee 1789 (49.1) 13551 (47.2) <0.001 
Tea  1200 (32.9) 8781 (30.6)  
Neither  658 (18.0) 6380 (22.2)  
    
Daily intake of stimulant 
drinks (cups/day), 
median (25th, 75th 
quartiles) 
2 [2, 4] 2 [2, 4] 0.011 
    
Physical Activity   (%)    
No physical activity 
weekly 
639 (17.5) 4584 (16.0) 0.023 
Light physical activity 
most weeks  
1850 (50.7) 14782 (51.5)  
At least 20 minutes 
vigorous physical 
activity once or twice a 
week  
567 (15.6) 4860 (16.9)  
At least 20 minutes 
vigorous physical 
activity at least three 
times a week  
591 (16.2) 4495 (15.7)  
CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; 
CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; 
CCS, Canadian Cardiovascular society; DBP, diastolic blood pressure; ECG, 
electrocardiogram; HBA1C, hemoglobin A1C, LBBB, left bundle branch block; 
NYHA, New York Heat Association; PCI, percutaneous coronary intervention; 
SBP, systolic blood pressure 
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Table 2. Baseline Cardiovascular Characteristics by Living Arrangement 
Status 
 Living alone 
(n=3648) 
Not living alone 
(n=28,728) 
p-value 
Any angina   (%) 840 (23.0) 6328 (22.0) 0.17 
Angina and CCS Class   0.13 
No Angina 2807 (77.0) 22399 (78.0)  
Angina CCS Class I  263 (7.2) 1788 (6.2)  
Angina CCS Class II  417 (11.4) 3396 (11.8)  
Angina CCS Class III  150 (4.1) 1075 (3.7)  
Angina CCS Class IV  10 (0.3) 68 (0.2)  
    
CHF symptoms including 
NYHA class 
  0.89 
No CHF   (%) 3098 (84.9) 24375 (84.9)  
CHF NYHA Class II  456 (12.5) 3642 (12.7)  
CHF NYHA Class III  94 (2.6) 709 (2.5)  
    
Heart Rate (palpation), mean 68.3 (10.6) 68.2 (10.6) 0.79 
SBP (mm Hg), mean 132.2 (17.2) 130.9 (16.6) <0.001 
DBP (mm Hg), mean 76.9 (10.1) 77.3 (10.0) 0.020 
Left Ventricular Ejection 
Fraction (%), mean 
56.5 (11.3) 56.0 (11.0) 0.032 
    
Number of vessels with 
disease  (%)* 
  0.005 
0 139 (4.6) 864 (3.5)  
1 1279 (41.9) 10053 (40.9)  
2 or more  1634 (53.5) 13649 (55.6)  
    
Coronary territories with 
stenosis >50%  (%)* 
   
Left Main 335 (9.2) 2500 (8.7) 0.33 
Left anterior descending  2075 (56.9) 16827 (58.6) 0.051 
Circumflex artery 1208 (33.1) 10468 (36.5) <0.001 
Right coronary artery  1520 (41.7) 12590 (43.8) 0.013 
Bypass Graft  299 (8.2) 2300 (8.0) 0.69 
No significant stenosis  146 (4.0) 906 (3.2) 0.007 
Coronary angiography not 
performed (within 12 months)  
586 (16.1) 4138 (14.4) 0.007 
    
**ECG Rhythm   (%)   <0.001 
Sinus rhythm  2462 (93.1) 20499 (95.2)  
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Atrial Fibrillation/Flutter  121 (4.6) 702 (3.3)  
Paced rhythm  62 (2.3) 332 (1.5)  
LBBB 158 (6.0) 1025 (4.8) 0.0063 
    
HbA1C (%), mean (SD) 6.7 (1.2) 6.8 (1.8) 0.018 
Creatinine (mmol/L), median 
(25th, 75th quartiles) 
87 [74, 100] 88 [76, 102] <0.001 
Hemoglobin (g/dL), median 
(25th, 75th quartiles) 13.9 [12.9, 14.9] 14.1 [13.0, 15.0] 
<0.001 
Fasting Blood Glucose 
(mmol/L), median (25th, 75th 
quartiles)  
5.6 [5.0, 6.5] 5.7 [5.1, 6.7] <0.001 
Total Cholesterol (mmol/L), 
median (25th, 75th quartiles) 
4.4 [3.7, 5.1] 4.3 [3.7, 5.0] 0.002 
HDL (mmol/L), median (25th, 
75th quartiles) 
1.2 [1.0, 1.5] 1.1 [1.0, 1.4] <0.001 
LDL (mmol/L), median (25th, 
75th quartiles) 
2.37 [1.89, 2.94] 2.37 [1.90, 2.94] 0.68 
Fasting Triglycerides (mmol/L), 
median (25th, 75th quartiles) 
1.39 [1.00, 1.88] 1.40 [1.02, 1.93] 0.15 
CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; CHF, 
congestive heart failure; COPD, chronic obstructive pulmonary disease; CCS, 
Canadian Cardiovascular society; DBP, diastolic blood pressure; ECG, 
electrocardiogram; HBA1C, hemoglobin A1C, LBBB, left bundle branch block; 
NYHA, New York Heat Association; PCI, percutaneous coronary intervention; SBP, 
systolic blood pressure 
* Investigators reported number of vessels with disease and number of coronary 
territories with significant stenosis (>50%) independent of whether the patient had 
a recent angiogram (within 12 months). This data was investigator reported 
independent of the most recent available angiogram results and may not be 
mutually exclusive.  
** Data was recorded if an ECG was available for whether the patient was in sinus 
rhythm, atrial fibrillation/atrial flutter, paced rhythm, or left bundle branch block 
(LBBB). The remaining patients may not have had ECG data available or may be in 
another rhythm then above. 
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Table 3. Medications and Reimbursement Status at Baseline by Living 
Arrangement Status 
 Living alone 
(N = 3648) 
Not living alone 
(N = 28728) p-value 
Medication (%)    
Aspirin  3154 (86.5) 25257 (87.9) 0.011 
Thienopyridine  835 (22.9) 7944 (27.7) <0.001 
Other Antiplatelets  291 (8.0) 2695 (9.4) 0.006 
≥2 antiplatelets 3644 (99.9) 28721 (99.9) <0.001 
Oral anticoagulants  299 (8.2) 2331 (8.1) 0.87 
Beta-Blockers  2652 (72.7) 21718 (75.6) <0.001 
Symptoms indicative of 
intolerance or contraindication 
to Beta-Blockers  
516 (14.2) 4167 (14.5) 0.56 
Ivabradine  330 (9.1) 2873 (10.0) 0.069 
Calcium antagonists  1057 (29.0) 7765 (27.0) 0.012 
ACE inhibitor or ARB 2790 (76.5) 21902 (76.2) 0.73 
Lipid-lowering drugs  3301 (90.5) 26598 (92.6) <0.001 
Statins 2954 (81.0) 23886 (83.2) 0.001 
Long-acting nitrates  764 (21.0) 6313 (22.0) 0.16 
Other antianginal agents  491 (13.5) 4030 (14.0) 0.36 
Diuretics  3154 (86.5) 25257 (88.0) 0.011 
Other antihypertensive agents  283 (7.8) 1946 (6.8) 0.027 
Digoxin and derivatives  108 (3.0) 706 (2.5) 0.067 
Amiodarone/Dronedarone  111 (3.0) 835 (2.9) 0.64 
Other antiarrhythmics  46 (1.3) 260 (0.9) 0.036 
NSAIDs  237 (6.5) 1350 (4.7) <0.001 
Antidiabetic agents  802 (23.0) 7126 (24.8) <0.001 
Proton pump inhibitors  987 (27.1) 7029 (24.5) <0.001 
Thyroid HRT  263 (7.2) 1144 (4.0) <0.001 
HRT in post-menopausal 
women  
16 (0.4) 82 (0.3) 0.11 
Erectile Dysfunction 60 (2.7) 459 (2.0) 0.04 
Reimbursement of 
cardiovascular agents (%) 
  <0.001 
Fully reimbursed 1612 (44.3) 11044 (38.5)  
Partly reimbursed  1363 (37.5) 10880 (37.9)  
Not reimbursed  665 (18.3) 6786 (23.6)  
 
In unadjusted models, patients living alone had a higher risk of the primary 
endpoint of MACE (10.3% vs 8.5%, HR 1.24, 95% CI 1.11-1.38, p<0.001), all-
cause death (9.8% vs 7.6%, HR 1.31, 95% CI 1.17–1.47, p<0.001), CV death 
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(6.5% vs 4.8%, HR 1.37, 95% CI 1.20-1.58, p<0.001), and stroke (2.7% vs 2.0%, 
HR 1.35, 95% CI 1.09-1.67, p=0.006). There was no difference in rates of MI, 
unstable angina, major bleeding or hospitalization for CHF (Table 4). After 
adjustment for age and sex, there remained statistically significant differences in 
the all-cause and CV death outcomes; following additional multivariate 
adjustment, there were no residual differences in outcomes in patients living 
alone compared to those living with others (Table 4).  
 
Table 4. Comparison of 5-year Cardiovascular Event Rates by Living 
Arrangement Status 
 
Outcome 5-year event rate (%) Time to First Event HR (95% CI) 
 Living 
Alone 
(N=3,648) 
Not Living 
Alone 
(N=28,728) 
Unadjusted 
Adjusted 
(age and 
sex) 
Adjusted* 
MACE 
10.3% 8.5% 
1.24 (1.11 - 
1.38), 
p<0.001 
1.11 (0.99 
– 1.24), 
p=0.07 
1.04 (0.92 
- 1.18), 
p=0.52 
All-cause 
death 9.8% 7.6% 
1.31 (1.17 - 
1.47),  
p <0.001 
1.13 (1.01 
– 1.26), 
p=0.04 
1.08 (0.95 
- 1.23), 
p=0.25 
CV death 
6.5% 4.8% 
1.37 (1.20 - 
1.58),  
p<0.001 
1.18 (1.02 
– 1.35), 
p=0.02 
1.12 (0.95 
- 1.32),  
p=0.17 
 MI 
3.5% 3.4% 
1.04 (0.86 - 
1.25),  
p=0.70 
1.01 (0.84 
– 1.22), 
p=0.93 
0.97 (0.78 
- 1.19), 
p=0.76 
Stroke 
2.7% 2.0% 
1.35 (1.09 - 
1.67),  
p=0.006 
1.15 (0.93 
– 1.43), 
p=0.20 
1.00 (0.77 
- 1.30), 
p=0.99 
Unstable 
angina 10.8% 11.0% 
0.99 (0.89 - 
1.10),  
p=0.86 
0.97 (0.87 
– 1.08), 
p=0.55 
0.99 (0.88 
- 1.12), 
p=0.91 
Major 
bleeding  1.4% 1.4% 
1.01 (0.75 - 
1.35),  
p=0.96 
0.90 (0.67 
– 1.21), 
p=0.48 
0.91 (0.66 
- 1.24), 
p=0.55 
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Hospitaliza
tion for 
CHF 
5.6% 5.2% 
1.10 (0.95 - 
1.28),  
p=0.20 
1.02 (0.87 
– 1.18), 
p=0.83 
1.07 (0.89,  
1.27),  
p=0.48 
*multivariate analysis adjusted for age, sex, geographical region, smoking status, 
diabetes, peripheral arterial disease, myocardial infarction, percutaneous 
coronary intervention, coronary artery bypass graft surgery, asthma/chronic 
obstructive pulmonary disease, congestive heart failure, systolic blood pressure, 
diastolic blood pressure, left ventricular ejection fraction, number of vessels with 
coronary artery stenosis. MACE reported as a composite of CV death, MI, or 
stroke. Abbreviations: CHF, congestive heart failure; CV, cardiovascular; MACE, 
major adverse cardiovascular events; MI, myocardial infarction 
 
 
Nevertheless, there was significant heterogeneity identified in the 
exposure effect by sex (Pinteraction <0.01) (Figure 1). Specifically, men living alone 
were at higher risk for MACE (HR 1.17, 95% CI 1.002–1.36, p=0.047) as 
opposed to women living alone (HR 0.82, 95% CI 0.65–1.04, p=0.099). This 
difference was primarily driven by effect modification by sex for MI (Pinteraction = 
0.006) with no difference in CV death (Pinteraction =0.075) and stroke (Pinteraction 
=0.99). Women living alone in comparison to women living with others showed a 
significantly lower adjusted risk of MI (2.2% vs 3.2%, HR 0.54, 95% CI 0.35–
0.84, p=0.007) that was not apparent in males (4.0% vs 3.2%, HR 1.17, 0.92–
1.49, p=0.19).  
The effect of living alone for MACE was consistent across age groups 
(<65 years, 65–74 years, ≥75 years, Pinteraction=0.33). There were potential 
varying effects of living alone by age group for MI (Pinteraction =0.046) and stroke 
(Pinteraction =0.05) (Figure 2). Specifically, the risk of MI tended to be lowest 
among older patients (≥75 years) living alone in comparison to older patients 
living with others (3.3% vs 4.2%, HR 0.67, 95% CI 0.43-1.04, p=0.077), 
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intermediate risk among middle age (65-74 years) patients (2.9% vs 3.4%, HR 
0.83, 95% CI 0.57–1.21, p=0.33), and highest among younger (<65 years) 
patients in the cohort (3.9% vs 2.9%, HR 1.31, 95% CI 0.96-1.78, p=0.088). 
Similar findings were observed for stroke (Figure 2). The effect of living alone 
was consistent in patients with and without prior MI (Pinteraction=0.44).  
 
DISCUSSION 
CLARIFY is the largest international registry to describe the association of living 
alone with CV outcomes in a contemporary population of patients with stable 
CAD. Despite an indication that people living alone had a higher incidence of 
several outcomes in unadjusted analyses including the primary endpoint of 
MACE, the results of the adjusted analysis revealed no independent risk of 
MACE in patients living alone. A novel aspect to our analysis is that we did 
observe potential sex-based heterogeneity for the effects of living alone. 
Specifically, women living alone had a trend towards lower risk of MI compared 
with women or men living with others. Older patients living alone demonstrated a 
trend towards a lower risk of MI and stroke, while the trends reversed for younger 
patients living alone.  
Recent studies have described the association of living alone with adverse 
events in patients with CVD. The Coronary Revascularization Demonstrating 
Outcome Study in Kyoto Acute Myocardial Infarction (CREDO-KYOTO) registry 
included patients with acute coronary syndrome (ACS) who underwent PCI; at 5-
year follow-up patients living alone did not have an increased risk of death or CV 
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events, however an increased risk of HF admission. Their study did not show 
heterogeneity in patients ≥75 years.(6) In patients post-ACS from Japan, The 
Osaka Acute Coronary Insufficiency Study (OACIS) registry showed patients 
living alone had overall increased MACE, with female patients living alone 
showing a trend towards increased risk.(13) The Reduction of Atherothrombosis 
for Continued Health (REACH) Registry was a large, prospective, observational 
registry with >40,000 patients with high vascular risk and established CVD. Their 
results showed that living alone was associated with an increased risk of 4-year 
mortality and CV death in patients with established CVD;(5) there was 
heterogeneity in risk of events according to age with lower risk in elderly patients 
>80 years old. In contrast to REACH, our analysis did not show a difference in 
all-cause and CV death according to living situation, potentially due to several 
reasons. Compared to REACH, patients included in the CLARIFY registry were 
younger, had less conventional risk factors and prior history of vascular disease, 
and represented a lower-risk population evident by the lower event rates for 
death and CV outcomes. Patients in the CLARIFY registry also were on more 
guideline-recommended secondary preventative therapy.  
The potential sex-specific differences in CV outcomes according to living 
situation supports previous literature exploring this association (Table 5).(5, 7, 
14-18)  
 
Table 5. Studies with Sex-specific Differences in Cardiovascular Outcomes 
According to Living Arrangement in patients with Cardiovascular Disease 
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Study (Year) Study 
Period/Location 
Patients 
included 
Outcomes 
Case (1992) 
(17) 
1983 – 1986, 
United States and 
Canada 
Randomized 
control trial (The 
Multicenter 
Diltiazem 
Postinfarction 
Trial) 
Age 25 – 75 
years, admitted to 
hospital with 
acute myocardial 
infarction 
Women living alone 
had risk for recurrent 
cardiac events (HR 
2.34, 95% CI 1.17 – 
4.66) as compared to 
men living alone (HR 
1.24, 95% CI 0.75.- 
2.03) 
Kilpi (2015) 
(14) 
1987 – 2007, 
Finland 
Population-based 
study 
Men and women 
living in a private 
household, 
previous coronary 
heart disease 
Men living alone had 
increased risk of 
long-term mortality 
compared to married 
men (OR 1.50, 95% 
CI 1.29 – 1.75, 
p<0.001) 
Kitamura 
(2013) (13) 
2002 – 2010, 
Japan 
Prospective, 
multicenter 
observational 
study 
Post-myocardial 
infarction 
Men living alone were 
associated with a 
higher risk of 
recurrent myocardial 
infarction (HR 1.71, 
95% CI 1.11 – 2.64) 
Women living alone 
had higher risk of 
stroke (HR 4.21, 95% 
CI 1.65 – 10.79) 
Lammintausta 
(2013) (16) 
1993 – 2002, 
Finland 
Population based 
registry 
Previous 
myocardial 
infarction 
Men and women 
living alone had 
higher case fatality 
rate. Men living alone 
received thrombolysis 
less often than men 
living with one or 
more people. 
O’Shea 
(2002) (18) 
1995 – 1997, 
Germany, United 
States 
Global Use of 
Strategies to Open 
occluded coronary 
arteries (GUSTO)-
III trial. 
 
Patients with 
acute myocardial 
infarction 
After adjustment, 
living alone was not 
an independent risk 
factor for 
cardiovascular 
outcomes with no 
heterogeneity 
identified according to 
gender.  
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Schmaltz 
(2007) (7) 
1998 – 1999, 
Canada 
Retrospective 
study 
Primary 
discharge 
diagnosis of 
acute myocardial 
infarction 
Men living alone had 
increased risk of 
death (HR 2.0, 95% 
CI 1.1-3.7), but not in 
women (HR 1.2, 95% 
CI 0.7-2.2). 
Udell (2012) 
(5) 
2003 – 2004, 44 
countries 
Prospective study 
Prior coronary, 
cerebrovascular, 
or peripheral 
artery disease, 
and participants 
without 
established 
atherothrombosis 
but at least 3 CV 
risk factors 
(diabetes 
mellitus, 
microalbuminuria, 
ankle-brachial 
index < 0.9, 
asymptomatic 
carotid stenosis 
of at least 70%, 
carotid intima 
media thickness, 
hypertension, 
dyslipidemia, 
current smoking, 
or age 65 years 
or older for men 
or 70 years or 
older for women).  
Living alone was 
associated with 
higher all-cause 
mortality (HR 1.24, 
p=0.04) and CV 
death (HR 1.29, 
p=0.04), however no 
heterogeneity 
identified according to 
sex.  
 
 
There are several mechanisms that may account for the discrepancy in 
CV events seen between men and women living alone. Historically, women 
manage the household and assume a nurturing role, and may develop superior 
self-care skills than their male counterparts. Women socialize differently than 
men and may form stronger social networks outside of their cohabitation, relying 
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less on spousal support compared to men.(19) Men living alone who were 
previously cohabitating with women may not have developed adequate 
independent coping mechanisms and social supports. This may lead to poor 
outreach with less attendance to physician appointments or cardiac rehabilitation, 
and seeking out medical attention when necessary.(20) Previous studies have 
shown heterogeneity between men and women in regards to stressful live events 
and social support and its impact on both health related quality of life, as well as 
psychological and physical function.(21) The difference in CV risk factors 
between women living alone and women living with others has not been clearly 
defined; women living alone may have an increased risk of developing diabetes, 
are more likely to smoke, and less likely to have hypertension.(20, 22) In the 
current era, women are more financially and socially independent than previous 
generations, with technology enhancing accessibility and communication. It may 
be that living status in women may not be as strong a reflection of social isolation 
compared to males. These suggestions are speculative as previous studies have 
failed to show this sex-based interaction identified in the CLARIFY registry.(5, 13, 
17, 18, 23) Further studies are warranted to assess factors that may attribute to 
the difference in CV risk in men and women living alone such as location of 
residence (urban or rural), social supports, social networks, local health care 
resources, as well as institutionalization, marital status, and progression of CV 
risk factors which may guide novel interventions to reduce recurrent CV events in 
men living alone. 
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Similar to findings from the REACH registry, we observed trends toward a 
lower risk of recurrent MI and stroke among elderly patients (≥75 years) living 
alone, while younger patients (<65 years) living alone had increased risk. 
Patients <65 years may have relatively complex social interactions with 
increased stress, anxiety and depression resulting in poor health behaviour with 
adverse hemodynamic effects which may lead to the progression of CVD. Elderly 
patients ≥75 years living alone may reflect those who have less comorbid 
conditions and are able to live independently, and do not require assisted living 
or nursing home level of care. Discharge planning in elderly patients is 
multifaceted with a focus on mobility, home safety, and methods to improve 
medication adherence with early and close outpatient follow-up. Lower CV 
events in elderly patients living alone may also represent the success of post-
discharge initiatives in this patient population. Our analysis suggests that there is 
not an association between elderly women living alone and increased risk for CV 
events but there may be in men; this finding is hypothesis generating and further 
analyses are needed to elucidate the potential mechanisms underlying this 
difference.   
With advancements in the management CAD, patients are living longer 
with improved health and functional status. For this reason, living situation is an 
important variable to account for and thus our analysis has several important 
implications. After adjustment, we did not identify that living alone is associated 
with an independent risk for MACE in patients with stable CAD. There was 
similar use of guideline recommended therapy in both living status groups. This 
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is in contrast to previous studies which suggest that patients living alone may be 
at increased risk of CV events. This may represent an improvement of care 
provided by clinicians managing these patients with increased long-term 
awareness of psychosocial issues, ensuring optimal care is delivered, potentially 
limiting the care gap in this patient population. Similarly, the suggested lower risk 
in elderly patients living alone may be a testament to close clinical follow-up and 
adequacy of social supports provided which allows these individuals to remain 
living alone in the community without institutionalization. The novel finding of 
potential lower CV risk in women warrants further assessment. Women living 
alone may have coping mechanisms that we were not able to identify in our 
analysis that may have accounted for this difference. As cardiovascular 
specialists caring for patients with established coronary artery disease, it is 
important to consider psychosocial factors such as living status which may 
increase cardiovascular risk. Physicians should counsel patients to report 
symptoms immediately without delay to medical attention and identify those that 
may benefit from further psychosocial intervention. Future studies can explore 
the role of interventional social support, such as cardiac rehabilitation, which may 
improve outcomes in these subgroups. To date, there is little trial data to show 
providing multidisciplinary social support improves outcomes following a cardiac 
event, but several years have passed and new methods of connectivity now exist 
that may improve effects.  
There are several limitations to our analysis. The case report form identified 
patients living alone at baseline, which we used as a marker of social isolation. 
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Specific details were not provided about living status including living conditions 
(type of residence), and proximity of social supports and resources, which may 
have further differentiated this heterogeneous population. In addition, we were 
not able to account or adjust for unidentified confounders such as stress, 
depression, and socioeconomic status. Unfortunately, this information is not 
available and although we tried to adjust for various patient characteristics, we 
acknowledge that there remains a potential for residual confounding. Physicians 
investigators completed the electronic case report form at baseline and yearly 
entering the patient information. It is unclear if the physician investigator 
contacted the patient directly or via relatives. Furthermore, study end points were 
determined by the site investigators without central adjudication. A previous 
study in young patients with MI demonstrated those with lower social support 
were more likely to live alone but also had poorer mental health status, quality of 
life scores, and more depression.(24) Further exploration between living status 
and mental health outcomes may give insight into this complex interaction. 
Patients excluded from the CLARIFY registry included those with serious non-
cardiovascular disease or conditions interfering with life expectancy (i.e. cancer, 
drug abuse) or severe cardiovascular disease such as advanced heart failure 
and were less likely to live alone; the impact this may have had on the analysis is 
speculative. Our case report form did not identify marital status, which may have 
given further insight into the heterogeneity of the risk of living alone in females 
and different age groups. For elderly patients, we were not able to use any other 
markers of functional status, which may have given further insight into CV risk. 
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Living status was recorded only at baseline and we were not able to describe 
how long each patient was living alone or account for the need for change in 
living status throughout the follow-up period. The case report form only identified 
clinical end points as described; we were not able to account for other markers of 
healthcare consumption such as hospitalisation or increased utilization of local 
health services.   
 
CONCLUSION 
Living alone in patients with stable CAD was not associated with an independent 
increase in MACE, although age and sex-based differences were apparent. 
Elderly patients and women living alone may have potentially lower CV risk. 
Future large studies in patients with established coronary artery disease should 
further evaluate key components of social isolation using validated in-depth 
tools/scoring systems. This will better inform us of higher risk components of 
social deprivation which will help guide potential psychosocial interventions. 
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FIGURE LEGENDS 
 
 
Figure 1: Forest plot: Event Rates, Adjusted Hazard Ratios, and Multivariate 
interaction by Sex according to Living Arrangement Status 
5-year event rate and hazard ratios (HRs) for the primary endpoint of MACE and 
secondary endpoints (all-cause death, CV death, MI and stroke) stratified by sex 
according to living arrangement status. Adjusted HRs associated with living alone 
compared with living with others (reference). The multivariate analysis was 
adjusted for age, sex, geographical region, smoking status, diabetes, peripheral 
arterial disease, myocardial infarction, percutaneous coronary intervention, 
coronary artery bypass graft surgery, asthma/chronic obstructive pulmonary 
disease, congestive heart failure, systolic blood pressure, diastolic blood 
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pressure, left ventricular ejection fraction, and number of vessels with coronary 
artery stenosis.  
 
 
 
 
Figure 2: Forest Plot: Event Rates, Adjusted Hazard Ratios, and 
Multivariate interaction by Age Group according to Living Arrangement 
Status 
5-year event rate and hazard ratios (HRs) for the primary endpoint of MACE and 
secondary endpoints (all-cause death, CV death, MI and stroke) stratified by age 
group according to living arrangement status. Adjusted HRs associated with 
living alone compared with living with others (reference). The multivariate 
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analysis was adjusted for age, sex, geographical region, smoking status, 
diabetes, peripheral arterial disease, myocardial infarction, percutaneous 
coronary intervention, coronary artery bypass graft surgery, asthma/chronic 
obstructive pulmonary disease, congestive heart failure, systolic blood pressure, 
diastolic blood pressure, left ventricular ejection fraction, number of vessels with 
coronary artery stenosis.  
 
 
 
 
 
 
 
 
 
